Tolerability of high-dose interferon alfa-2b in patients with high-risk melanoma

A. S. Vichrova; Вихрова А. С.; K. V. Orlova; Орлова К. В.; I. V. Samoylenko; Самойленко И. В.; G. Yu. Kharkevich; Харкевич Г. Ю.; L. V. Demidov; Демидов Л. В.

Tolerability of high-dose interferon alfa-2b in patients with high-risk melanoma

Authors: Vichrova A.S.¹, Orlova K.V.¹, Samoylenko I.V.¹, Kharkevich G.Y.¹, Demidov L.V.¹
Affiliations:
1. N.N. Blokhin Russian Cancer Research Center Ministry of Health of the Russian Federation
Issue: Vol 8, No 1 (2016)
Pages: 56-64
Section: TUMORS OF THE SKIN
Published: 22.01.2016
URL: https://sarbon.abvpress.ru/jour/article/view/387
ID: 387

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Despite therapeutic advances in metastatic melanoma, fundamental changes in the section of adjuvant therapy has not yet come. The problem of adjuvant therapy in cutaneous melanoma in Russia is of particular importance due to the large proportion of advanced forms of the disease in the patient population with the local and regional stages. To date, it is shown that recombinant interferon alpha-2a and alpha-2b (IFN alpha) are an effective drugs for adjuvant therapy melanoma. high-dose interferon alpha-2b (HDI) is the standard treatment in the Us in patients with IIB–III melanoma stages. In this article we consider the portability of hdI during adjuvant therapy in patients with high-risk melanoma in a specialized department.